Forte Biosciences Inc. (NASDAQ: FBRX) announced the pricing of a public offering of 5,709,936 shares of common stock at $26.27 per share. The clinical-stage biopharmaceutical company also granted underwriters a 30-day option to purchase up to an additional 856,490 shares at the same price.

The gross proceeds from the offering are expected to reach approximately $150 million before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on or about April 10, 2026, subject to customary closing conditions.

Forte plans to use the net proceeds for working capital and general corporate purposes, including funding clinical development of its product candidate and research activities. The company is developing FB102, an anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related conditions.

Guggenheim Securities and Barclays are serving as joint book-running managers for the offering. The offering is being conducted under a Registration Statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission.

All shares in the offering are being sold by Forte Biosciences. The information is based on a company press release.